These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 23928897)

  • 1. Safety of off-label erythropoiesis stimulating agents in critically ill patients: a meta-analysis.
    Mesgarpour B; Heidinger BH; Schwameis M; Kienbacher C; Walsh C; Schmitz S; Herkner H
    Intensive Care Med; 2013 Nov; 39(11):1896-908. PubMed ID: 23928897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harms of off-label erythropoiesis-stimulating agents for critically ill people.
    Mesgarpour B; Heidinger BH; Roth D; Schmitz S; Walsh CD; Herkner H
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD010969. PubMed ID: 28841235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data.
    Bohlius J; Tonia T; Nüesch E; Jüni P; Fey MF; Egger M; Bernhard J
    Br J Cancer; 2014 Jul; 111(1):33-45. PubMed ID: 24743705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
    Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C
    Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoiesis-stimulating agents in gynecological malignancies: A study-level meta-analysis.
    Marchetti C; De Felice F; Palaia I; Musio D; Muzii L; Tombolini V; Benedetti Panici P
    Crit Rev Oncol Hematol; 2016 Mar; 99():123-8. PubMed ID: 26748593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoiesis-stimulating Agents in Critically Ill Trauma Patients: A Systematic Review and Meta-analysis.
    French CJ; Glassford NJ; Gantner D; Higgins AM; Cooper DJ; Nichol A; Skrifvars MB; Imberger G; Presneill J; Bailey M; Bellomo R
    Ann Surg; 2017 Jan; 265(1):54-62. PubMed ID: 27070933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of erythropoiesis‑stimulating agents on lung cancer patients: a meta‑analysis.
    Tong Z; Xu Z; Duan Y; Sun X; Qi B
    Clin Exp Med; 2024 Jul; 24(1):150. PubMed ID: 38967734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of erythropoiesis-stimulating agents in the treatment of anemia in patients with systolic heart failure.
    Lindquist DE; Cruz JL; Brown JN
    J Cardiovasc Pharmacol Ther; 2015 Jan; 20(1):59-65. PubMed ID: 24996902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
    Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
    Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On-label and off-label prescribing patterns of erythropoiesis-stimulating agents in inpatient hospital settings in the US during the period of major regulatory changes.
    Seetasith A; Holdford D; Shah A; Patterson J
    Res Social Adm Pharm; 2017; 13(4):778-788. PubMed ID: 27595426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten years of meta-analyses on erythropoiesis-stimulating agents in cancer patients.
    Tonia T; Bohlius J
    Cancer Treat Res; 2011; 157():217-38. PubMed ID: 21052959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
    Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
    Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis.
    Gao S; Ma JJ; Lu C
    Tumour Biol; 2014 Jan; 35(1):603-13. PubMed ID: 23959477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of erythropoiesis-stimulating agents in critically ill patients admitted to the intensive care unit: a systematic review and meta-analysis.
    Litton E; Latham P; Inman J; Luo J; Allan P
    Intensive Care Med; 2019 Sep; 45(9):1190-1199. PubMed ID: 31297547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: A meta-analysis of randomized clinical trials.
    Kang J; Park J; Lee JM; Park JJ; Choi DJ
    Int J Cardiol; 2016 Sep; 218():12-22. PubMed ID: 27209352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacovigilance in practice: erythropoiesis-stimulating agents.
    Hedenus M; Ludwig H; Henry DH; Gasal E
    Cancer Med; 2014 Oct; 3(5):1416-29. PubMed ID: 24890561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of Physiological Erythropoiesis in the Treatment of Chronic Kidney Disease-Associated Anemia.
    Kuragano T; Nakanishi T
    Contrib Nephrol; 2018; 196():52-57. PubMed ID: 30041204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of erythropoiesis-stimulating agents in acute ST-segment elevation myocardial infarction: a systematic review.
    Li J; Xu H; Gao Q; Wen Y
    Eur J Clin Pharmacol; 2012 May; 68(5):469-77. PubMed ID: 22086550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Cardiovascular Adverse Effects of Erythropoiesis Stimulating Agents in the Treatment of Cancer-Related Anemia: A Systematic Review of Randomized Controlled Trials.
    Gergal Gopalkrishna Rao SR; Bugazia S; Dhandapani TPM; Tara A; Garg I; Patel JN; Yeon J; Memon MS; Muralidharan A; Khan S
    Cureus; 2021 Sep; 13(9):e17835. PubMed ID: 34527499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.
    Cortegiani A; Russotto V; Maggiore A; Attanasio M; Naro AR; Raineri SM; Giarratano A
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD004920. PubMed ID: 26772902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.